Citations

Clear

1792 citation(s) found for "Stephanie".

Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
Buckner, Jan C. , Pugh, Stephanie L. , Shaw, Edward G. , Barger, Geoffrey, Coons, Stephen W., Ricci, Peter E. , Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , Brachman, David, Schultz, Christopher J. , Bahary, Jean-Paul , Fisher, Barbara J., Kim, Harold , Murtha, Albert , Curran, Walter J. , Gilbert, Mark R. , Suh, John H. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2000-2000

10.1200/jco.2014.32.15_suppl.2000 Get It

Voice outcomes following medialization laryngoplasty with and without arytenoid adduction
Zimmermann, Terence M., Orbelo, Diana M. , Pittelko, Rebecca L. , Youssef, Stephanie J. , Lohse, Christine M. , Ekbom, Dale C. , Orbelo, Diana

Mayo Clinic

The Laryngoscope | December 24, 2018 | Volume: 129 | Issue: 8 | Pages: 1876-1881

10.1002/lary.27684 | PMID 30582612 Get It

ObjectiveVoice outcomes following medialization laryngoplasty (ML) for unilateral vocal fold paralysis (UVFP) were compared to those who underwent ML plus arytenoid adduction (AA) (ML+AA).MethodsSingle institution retrospective review of patients with UVFP undergoing ML and ML+AA (2009–2017). Demographic information and history of laryngeal procedures were collected. Preoperative and postoperative Voice Handicap Index‐10 (VHI‐10) and Consensus Perceptual Auditory Evaluation of Voice (CAPE‐V) were assessed.ResultsOf 236 patients, 119 met study criteria. Of those, 70 (59%) underwent ML and 49 (41%) underwent ML+AA. Significant differences between groups at baseline were found for age at time of thyroplasty (P = 0.046), VHI‐10 scores (P < 0.001), and CAPE‐V scores (P = 0.007). Baseline VHI‐10 scores for ML+AA (28 ± 7) were greater than those for ML alone (24 ± 7). At 12 months, overall VHI‐10 scores improved compared to baseline for both groups (ML+AA = 9 ± 7, ML = 16 ± 9); however, there was greater improvement for the ML+AA group compared to ML group (P = 0.001). CAPE‐V scores at 3 or 12 months improved, but differences between the groups were not statistically significant once controlled for covariates.ConclusionBased on current findings, patients who undergo ML+AA likely have greater voice handicap at baseline compared to those undergoing ML alone. Patients selected for ML+AA improve as much or more than those who underwent ML alone. This highlights the importance of appropriate selection of candidates for AA.Level of Evidence4Laryngoscope, 129:1876–1881, 2019
IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes
Fang, Hong , Reichard, Kaaren K. , Rabe, Kari G. , Hanson, Curtis A. , Call, Timothy G. , Ding, Wei , Muchtar, Eli , Schwager, Susan M., Leis, José F., Chanan‐Khan, Asher , Braggio, Esteban , Smoley, Stephanie A., Shanafelt, Tait D. , Dyke, Daniel L. Van , Kenderian, Saad S. , Chanan-Khan, Asher A., Van Dyke, Daniel L, Chaffee, Kari G. , Ding, Wei , Muchtar, E , Shanafelt, Tait D , Braggio, Esteban , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

American Journal of Hematology | December 21, 2018 | Volume: 94 | Issue: 3 | Pages: 338-345

10.1002/ajh.25385 | PMID 30575108 Get It

The prevalence, clinicopathologic correlates, and outcomes of previously untreated chronic lymphocytic leukemia (CLL) patients with IGH‐BCL2 and IGH‐BCL3 translocations are not well known. Using the Mayo Clinic CLL database, we identified patients seen between March 1, 2002 and September 30, 2016 who had FISH testing performed within 3 years of CLL diagnosis. The prognostic profile, time to first therapy (TTT), and overall survival (OS) of patients with IGH‐BCL2 and IGH‐BCL3 translocation were compared to patients without these abnormalities (non‐IGH group). Of 1684 patients who met the inclusion criteria, 38 (2.2%) had IGH‐BCL2, and 16 (0.9%) had IGH‐BCL3 translocation at diagnosis. Patients with IGH‐BCL3 translocation were more likely to have high and very‐high CLL‐International Prognostic Index, compared to patients with IGH‐BCL2 translocation and the non‐IGH group. The 5‐year probability of requiring therapy was significantly higher for IGH‐BCL3 compared to IGH‐BCL2 and non‐IGH groups (84% vs 33% vs 29%, respectively, P < 0.0001). The 5‐year OS was significantly shorter for IGH‐BCL3 compared to IGH‐BCL2 and non‐IGH groups (45% vs 89% vs 86%, respectively, P < 0.0001). On multivariable analyses, IGH‐BCL3 translocation was associated with a shorter TTT (hazard ratio [HR] = 2.7; P = 0.005) and shorter OS (HR = 5.5; P < 0.0001); IGH‐BCL2 translocation did not impact TTT and OS. In conclusion, approximately 3% of all newly diagnosed CLL patients have either an IGH‐BCL2 or IGH‐BCL3 translocation. Patients with IGH‐BCL3 translocations have a distinct prognostic profile and outcome. These results support the inclusion of an IGH probe during the routine evaluation of FISH abnormalities in newly diagnosed CLL.
287: THYROTOXICOSIS-INDUCED ACUTE HEART FAILURE TREATED WITH EXTRACORPOREAL MEMBRANE OXYGENATION
Shen, Stephanie

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 125-125

10.1097/01.ccm.0000551041.36425.e8 Get It

Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional–structural assessments via protein
Hines, Stephanie L., Jackson, Jessica L. , Macklin, Sarah , Caulfield, Thomas R. , Caulfield, Thomas R , Mohammad, Ahmed N.

Mayo Clinic

Molecular Omics | December 18, 2018 | Volume: 15 | Issue: 1 | Pages: 59-66

10.1039/c8mo00137e | PMID 30633282 Get It

Abstract The CHEK2 gene and its encoded protein Chk2 have a well-known role in cancers, especially those related to breast cancer mediated through the BRCA1 gene. Additionally Chk2 has a crucial role in DNA repair, apoptosis and the cell cycle, which is why classification of variants of uncertain significance (VUS) is an area highly sought for a better elucidation of the “genomic effect” that results. Because it can often take years before enough clinical data is accumulated, and the costly and expensive functional analysis for individual variants presents a significant hurdle, it is important to identify other tools to help aid in clarifying the impact of specific variants on a protein's function and eventually the patient's health outcome. Here we describe a newly identified CHEK2 variant and analyze with an integrated approach combining genomics (whole exome analysis), clinical study, radiographic imaging, and protein informatics to identify and predict the functional impact of the VUS on the protein's behavior and predicted impact on the related pathways. The observed and analyzed defects in the protein were consistent with the expected clinical effect. Here, we support the use of personalized protein modeling and informatics and further our goal of developing a large-scale protein deposition archive for all protein-level VUS.
A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
Lin, Alexander J. , Samson, Pamela , DeWees, T.A. , Henke, Lauren E. , Baranski, Thomas , Schwarz, Julie K. , Pfeifer, John D. , Grigsby, Perry W. , DeWees, Todd, DeWees, Todd A , Markovina, Stephanie T.

Mayo Clinic

Cancer Medicine | December 15, 2018 | Volume: 8 | Issue: 1 | Pages: 437-446

10.1002/cam4.1857 | PMID 30552739 Get It

AbstractBackgroundPrognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes.MethodsIn patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes.ResultsA total of 231 patients had archived formalin‐fixed, paraffin‐embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3‐6.0).ConclusionCharacterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.
The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy
Laack, Nadia N., Pugh, Stephanie L. , Brown, Paul D. , Fox, Sherry, Choucair, Ali, Khuntia, Deepak , Wendland, Merideth M, Meyers, Christina, Fox, Sherry, Wefel, Jeffrey S. , Meyers, Christina , Suh, John H. , Roberge, David , Bruner, Deborah Watkins

Mayo Clinic

Neuro-Oncology Practice | December 3, 2018 | Volume: 6 | Issue: 4 | Pages: 274-282

10.1093/nop/npy038 | PMID 31386073 Get It

Abstract Background This study evaluated the association between health-related quality of life (HRQOL) and cognition in patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT). Methods Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine, 20 mg per day, within 3 days of initiating radiotherapy, for 24 weeks. The Functional Assessment of Cancer Therapy-Brain module (FACT-Br) and Medical Outcomes Scale-Cognitive Functioning Scale (MOS-C) were completed in coordination with serial standardized tests of cognitive function. Results Of the 508 eligible patients, 442 (87%) consented to participate in the HRQOL portion and contributed to baseline analyses. Evaluable patients at 24 weeks (n = 246) included surviving patients completing FACT-Br, MOS-C, and objective cognitive assessments (n = 146, 59%) and patients alive at time of missed assessment (n = 100, 41%). Baseline cognitive function correlated significantly with FACT-Br and MOS-C self-reports. All domains of objective cognitive function showed declines over time. Neither FACT-Br nor MOS-C differed between the treatment arms. Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable. MOS-C scores declined over time. Conclusion Baseline cognitive function correlated significantly with FACT-Br and MOS-C scores. No by-arm differences in HRQOL were observed despite differences in objective cognitive function. Patient attrition and poor testing compliance remain significant problems in studies of cognitive function of brain metastases patients and further effort is needed to improve compliance with testing and sensitivity of patient-reported measures.
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Zvinovski, Filadelfiya , Hudson, Catherine O., Hundley, Andrew F., Evans, Cynthia, Suresh, Anupama , Stephens, Julie , Carpenter, Kristen M. , Ramaswamy, Bhuvaneswari , Reinbolt, Raquel E. , Williams, Nicole , Sardesai, Sagar , Loprinzi, Charles L. , Sardesai, Sagar , Quick, Allison , Noonan, Anne M. , VanDeusen, Jeffrey , Wesolowski, Robert , Stover, Daniel G. , Smith, Karen L. , Faubion, Stephanie S. , Lustberg, Maryam B.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 202-202

10.1200/jco.2018.36.34_suppl.202 Get It

202 Background: Fractional CO2 laser therapy is an emerging treatment for GSM. The objective of this study was to determine the feasibility, tolerability and preliminary efficacy of fractional CO2 laser therapy in BC survivors. Methods: This was a single arm feasibility study of BC survivors with dyspareunia and/or vaginal dryness. Participants received three treatments with office-based fractional CO2 laser on at least 30 day intervals and returned for a one-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in a minimum of 80% of patients. Primary efficacy was evaluated using the mean change (∆) in the score on the Vaginal Assessment Scale (VAS). Secondary efficacy endpoints included mean ∆ in scores on the Female Sexual Function Index (FSFI) and Urogenital Distress Inventory (UDI). Descriptive statistics (means and 95% confidence intervals (CI) for continuous variables and proportions for categorical variables) were used. Results: The study is ongoing with 65 patients enrolled. To date, 37 patients have completed all study treatments and follow-up. Median age for those who have completed treatment was 57 years (range 34-72). Most were ER/PR positive (78%) and Her 2 negative (81%) with stage I (43%) or II (41%) BC. Ninety-five percent were receiving endocrine therapy, most commonly aromatase inhibitors (73%). No SAEs were reported in the 37 patients who have completed study treatments and their outcomes are as follows. Based on the VAS, 78% reported moderate-severe dyspareunia and 89% reported moderate-severe vaginal dryness at baseline. At follow up, 28% reported moderate-severe dyspareunia and 28% reported moderate-severe vaginal dryness. The VAS score improved from baseline to follow up (mean ∆ 4.1; 95% CI [3.1, 5.1]). Similarly, the FSFI score improved (mean ∆ -10.0; 95% CI [-13.2, -6.9]) and the UDI score improved (mean ∆ -5.7; 95% CI [-10.1, -1.3]). Final efficacy analysis will be reported once all patients have completed all time points. Conclusions: Fractional CO2 laser treatment is feasible and tolerable in BC survivors and may reduce symptom burden from GSM. A randomized controlled trial with sham laser is currently in development. Clinical trial information: NCT03307044.